YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Starting June 1, Fidelity will charge a $100 fee on purchase trades on more than 120 exchange-traded funds (ETFs). It's one of the most investor-unfriendly decisions I've seen in a while. It started with Fidelity requiring ETF issuers to p…
Key Points Starting June 1, Fidelity will begin charging a $100 fee on purchase trades on more than 120 different ETFs. Many ETFs impacted are very small, but some big ones, such as the Roundhill Magnificent Seven ETF, will be subject to t…
BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined with PD-1 blockade LUND, SE / ACC…
24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile…
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunoth…
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunoth…
BT-001, administré en combinaison avec pembrolizumab, est bien toléré et présente une activité antitumorale persistante dans des lésions injectées et non-injectées Les résultats obtenus soutiennent la poursuite du développement de BT-001 d…
Transgene S.A. BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to…
Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m. CEST – Transgene (Euronext Paris: TNG), a…
La présentation d’un poster de BT-001 en combinaison avec pembrolizumab montre une réduction tumorale dans des lésions injectées et non injectées Strasbourg, France, et Lund, Suède, le 13 octobre 2025, 8 h 30 – Transgene (Euronext Paris :…
LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies…
As Europe navigates a landscape marked by tentative optimism surrounding an EU-U.S. trade deal and the European Central Bank's steady interest rates, the pan-European STOXX Europe 600 Index has seen modest gains, reflecting a cautious yet…
Poster presentation of updated data on BT-001 from the Phase I part of the ongoing Phase I/IIa study in solid tumors Strasbourg, France, and Lund, Sweden, July 28, 2025, 8:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company t…
Présentation d’un poster sur des données mises à jour de la partie Phase I de l’étude en cours de Phase I/IIa de BT-001 dans les tumeurs solides Strasbourg, France, et Lund, Suède, le 28 juillet 2025, 8 h 30 – Transgene (Euronext Paris : T…
LUND, SE / ACCESSWIRE / April 7, 2022 / BioInvent International (STO:BINV) BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2021 has been published. The Annual Report is attached to this…
LUND, SWEDEN / ACCESSWIRE / March 28, 2022 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., Th…